Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Don't Floss, You Lose - (ATRX) To the RESCUE. -- Ignore unavailable to you. Want to Upgrade?

To: Fred McCutcheon who wrote (162)	6/22/2000 1:20:00 PM
From: Fred McCutcheon	Read Replies (1) \| Respond to of 182

Thursday June 22, 11:12 am Eastern Time Company Press Release SOURCE: Atrix Laboratories, Inc. Atrix Forms Partnership With Elan Focused on Oncology And Pain Management Products FORT COLLINS, Colo., June 22 /PRNewswire/ -- Atrix Laboratories (Nasdaq: ATRX - news) today announced that they have signed an agreement with Elan Corporation, plc to form a research joint venture to develop and commercialize oncology and pain management products. As part of the agreement, Elan will provide funding to develop these compounds. Atrix will initially be the majority owner of the joint venture. Additionally, Elan will make an equity investment of $5 million in Atrix at a premium to market. This collaboration will use Atrix's patented BEMA(TM) and ATRIGEL© systems and Elan's NanoCrystal(TM) technology to deliver compounds targeted for major unmet medical needs, including control of side effects associated with chemotherapy or radiation therapy, rapid relief of break-through cancer pain and tumor directed cytotoxic agents. Dr. Larry Sternson, President of Elan Pharmaceutical Technologies, said, ``We are pleased with the opportunity to invest in, and collaborate with, Atrix. We look forward to working with a highly innovative company like Atrix that has a leading position in polymer-based, biodegradable drug delivery systems. The potential development of oncology and pain products and the exploitation of the synergies between both companies' proprietary platform technologies, represents a tremendous opportunity to build value for both Elan and Atrix. This collaboration is consistent with Elan's long-term strategy of building multiple alliances with strong emerging technology companies.'' David R. Bethune, chairman and chief executive officer of Atrix, said, ``This long-term joint venture brings together Atrix, an emerging leader in parenteral drug delivery technologies and Elan, the industry leader in oral drug delivery technology, with the shared goal of accelerating the development and commercialization of a variety of oncology and pain management products. With Elan, we now have the technical and financial resources to further advance the formulation and development of our platform technologies. ``Dr. Sternson and his drug delivery team at Elan have an outstanding track record of capitalizing on new technologies to bring products into the market,'' said Bethune. ``We believe that this agreement will create significant value for both companies. Speaking on behalf of the Atrix management team and the board of directors, we are delighted to have Elan, a world-class, high growth company, as our partner.'' Atrix Laboratories, Inc. is a drug delivery and drug development company whose patented technologies provide drug delivery from ``minutes to months.'' Atrix develops medical, dental and veterinary products in-house and also partners with large pharmaceutical and biotechnology companies to apply its proprietary technologies to new chemical entities or to extend the life cycle of existing products. Additional information is available on the Atrix Laboratories, Inc. Web site at atrixlabs.com. Statements contained in this press release, which are not historical facts, are forward-looking statements, as the term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated, due to a number of factors, which include, but are not limited to, product demand, pricing, market acceptance, changing economic conditions, risks in product and technology development, the effect of the company's accounting policies and other risk factors discussed in documents filed by the company with the Securities and Exchange Commission from time to time. SOURCE: Atrix Laboratories, Inc.